Barclays Cuts Medline (MDLN) Price Target to $43

Barclays has reiterated its Overweight rating on Medline Inc. with a new price target of $43.00, a 18.31% upside from the current price.

By EarningsIQ Research Desk · Published Oct 16, 2026, 2:16 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Barclays cut its price target on Medline Inc. ($MDLN) to $43 from $45 on October 9, 2026, and rates the stock "Overweight".

Since the rating, $MDLN is down 0.8% after 1 week and down 0.8% to date (from the $36.26 close on Oct 9, 2026).

MDLN Medline Inc.

$35.96 -11.47% year to date

Daily close · Oct 16, 2026

Key Points

On October 9, 2026, Barclays reiterated its Overweight rating on Medline Inc. with a price target of $43.00, down from $45.00.
Barclays's $43 price target implies 18.31% upside from Medline Inc.'s ($MDLN) current $36.34 share price.
The stock recently traded around $36.34, which is about 15.5% below Barclays' target price.
Medline is set to report earnings on November 4, 2026, following a year-over-year revenue growth of 11.6%.

Get $MDLN trade alerts by text

We text you when insiders, Congress or big funds trade $MDLN. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Medline Inc. alert may contain errors. Disclosures

Barclays has reiterated its Overweight rating on Medline Inc. (NasdaqGS: MDLN) and set a new price target of $43.00 on October 9, 2026. This target is a reduction from the previous $45.00. The stock has been trading recently around $36.34, which is approximately 15.5% below the new target price.

Other Institutional Activity in Medline Inc.

Carlyle Group Inc. holds 187,083,713 shares of Medline, valued at about $6.73 billion. Blackstone Inc. reduced its position by 22,404,953 shares, now holding 101,791,008 shares worth approximately $3.66 billion. H&F Corporate Investors X, Ltd. decreased its holdings by 15,599,963 shares, ending with 70,874,326 shares valued at about $2.55 billion. FMR, LLC increased its stake by 10,407,429 shares, bringing its total to 46,963,203 shares worth about $1.69 billion, while Capital Research Global Investors added 16,801,747 shares for a total of 39,963,790 shares valued at around $1.44 billion.

Medline Inc. Stock Up 14.9%

Medline's stock is currently trading below its new price target after the recent rating by Barclays. The shares recently traded around $36.34, which is significantly lower than the $43.00 target set by Barclays. This suggests potential challenges ahead for the stock.

12-month forecast

$MDLN price target

Medline Inc. daily closes and this analyst's $43 target. Not advice.

Recent Earnings

For the trailing twelve months, Medline reported revenue of approximately $29.94 billion and a net margin of 2.3%. The company has shown a year-over-year revenue growth of 11.6%. Medline is scheduled to announce its next earnings on November 4, 2026.

Insider Buying and Selling at Medline Inc.

GIC Private Ltd., a beneficial owner of more than 10% of Medline's securities, has sold several large blocks of shares recently. On August 7, 2026, it sold 590,284 shares at an average price of $35.58, totaling about $21 million. The firm also sold 1,600,000 shares on August 14 at $35.80, worth around $57.3 million. Most recently, on October 6, GIC sold 20,678,630 shares without a specified price, valued at approximately $721.6 million, and on October 8, it sold 7,816,987 shares at $35.15, totaling roughly $274.8 million.

Analysts Set New Price Targets

On October 9, 2026, Barclays maintained its Overweight rating on Medline and adjusted the price target to $43.00 from $45.00. Other analysts have also weighed in on Medline: Tigress Financial maintains a Buy rating with a target of $55.00; JP Morgan keeps an Overweight rating with a target of $46.00; BTIG reiterates a Buy rating with a target of $55.00; and UBS maintains a Buy rating with a price target of $43.00.

About Medline Inc.

Medline Inc. manufactures medical and surgical products for hospitals, surgery centers, and other healthcare facilities. It operates in two segments: Medline Brand and Supply Chain Solutions, focusing on a wide range of medical supplies used in various care settings. The recent analyst activity reflects ongoing interest in the company's performance within the healthcare sector.

Bottom Line

Investors should watch for Medline's upcoming earnings report on November 4, 2026. With Barclays' recent rating and target adjustment, the market will be keen to see how Medline performs in the coming quarters.